DSM Biomedical Expands Presence In US, Europe

DSM Biomedical said that the expansion is to support the growing demand for its portfolio of polyurethanes for chronically implanted medical devices in the regions.

Earlier, DSM Biomedical had expanded the role of two of its business development managers, one in the US and one in Europe, and an application development manager, based in Europe, to enhance its client relationships in the US and Europe and offer an improved level of on-the-ground technical assistance for customers.

DSM Biomedical said that all three experts will be responsible for key business development activities, representing the broader portfolio of DSM Biomedical, including managing customer relationships and providing technical assistance in the European and US Markets.

DSM Biomedical’s business expansion comes on the heels of its recent announcement that it signed nine new license agreements in 2009 for Bionate, BioSpan, CarboSil, Elasthane and PurSil brands of biomedical polymers, and formed eight new development partnerships with medical device companies in the last year alone, said the company. .

Bob Ward, president and CEO at DSM PTG, part of DSM Biomedical, said: “Medical device manufacturers are fast recognising a growing need for high performance, cost effective, and easy to implant devices produced from proven materials that have the potential to improve patient outcomes.

“With the company’s 20 years of experience developing innovative solutions for the medical device market as well as our recent investment in business and application development, we hope to not only offer a broader portfolio of solutions but also enable a faster material selection and design process based on proven materials, and ultimately device approvals for our clients and patients.”